2024-11-02 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis Report

**Company Overview:** Eli Lilly and Co. is a global pharmaceutical company that develops, manufactures, and markets a wide range of medicines, including diabetes treatments, oncology therapies, and autoimmune disease treatments.

**1. Performance Comparison:**

* **LLY Cumulative Return:** 790.13%
* **VOO (S&P 500) Cumulative Return:** 131.38%
* **Return Difference:** 658.75%
* **Relative Outperformance:** 82.09%

**LLY has significantly outperformed the S&P 500, showing a strong relative performance compared to the broader market.** The stock has consistently generated higher returns than the benchmark index.

**2. Recent Price Movement:**

* **Closing Price:** 829.74
* **Last Market:** 819.99
* **5-Day Moving Average:** 873.69
* **20-Day Moving Average:** 901.72
* **60-Day Moving Average:** 913.57

**The stock is currently trading below its 5-day, 20-day, and 60-day moving averages, indicating a short-term downtrend.** The recent market price suggests a potential pullback. 

**3. Technical Indicators:**

* **RSI:** 14.02 - **Oversold**: This indicates that the stock is currently oversold, suggesting potential for a rebound.
* **PPO:** -0.85 - **Negative**: This suggests that the stock is experiencing weakness and bearish momentum.
* **Delta_Previous_Relative_Divergence:** -7.23 - **Short-term Downward Trend:** This indicates a potential downward trend in relative performance compared to the market.
* **Expected Return:** 97.48% - **High Potential**:  The expected return suggests that long-term investors may benefit from potential outperformance compared to the S&P 500.

**4. Recent Earnings Performance and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-10-30 | 1.08 | 11.44 B$ |
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2024-10-30 | -0.06 | 9.50 B$ |

* **Latest Earnings (2024-10-30):** The company reported earnings per share of $1.08, surpassing analysts' expectations. Revenue came in at $11.44B, also exceeding estimates. 
* **Overall Trend:** Lilly has been consistently growing its revenue and profitability, demonstrating strong financial performance.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $11.44B | 81.02% |
| 2024-06-30 | $11.30B | 80.80% |
| 2024-03-31 | $8.77B | 80.91% |
| 2023-12-31 | $9.35B | 80.88% |
| 2023-09-30 | $9.50B | 80.42% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $14.24B | 6.81% |
| 2024-06-30 | $13.56B | 21.88% |
| 2024-03-31 | $12.81B | 17.51% |
| 2023-12-31 | $10.77B | 20.33% |
| 2023-09-30 | $11.22B | -0.51% |

* **Strong Performance:** Lilly has consistently demonstrated strong profitability and a healthy return on equity. The company's financial performance is robust, showing sustainable growth.

**6. News and Recent Issues:**

* **Earnings Release:** Lilly exceeded earnings expectations in the most recent quarter, as reported on October 30th. This positive performance was well-received by analysts. 
* **Market Outlook:** The stock is currently being observed by analysts for potential short-term volatility, as it trades below its moving averages. However, long-term prospects remain positive. 
* **Analyst Opinions:**  Many analysts remain bullish on LLY, citing its strong pipeline of drugs, consistent financial performance, and potential for growth. 

**7. Overall Analysis:**

Eli Lilly and Co. (LLY) presents a compelling investment opportunity for long-term investors. Despite the recent market correction and short-term volatility, the company has a strong track record of growth, consistent profitability, and a promising drug pipeline. 

**Key highlights include:**

* **High Outperformance:** LLY has consistently outperformed the S&P 500, demonstrating strong market resilience.
* **Solid Financial Performance:** The company has consistently generated strong revenue and profitability, showing a stable financial foundation.
* **Promising Pipeline:** Lilly continues to develop and launch new drugs, indicating potential for future growth.
* **High Expected Return:** The long-term expected return for LLY suggests potential for significant outperformance compared to the broader market.

However, potential investors should be aware of the recent short-term downtrend and potential for volatility, as the stock is currently trading below its moving averages.

Overall, LLY appears to be a strong investment option for investors seeking a stable and growing company with long-term growth potential.
